AORTIC VALVE & CONDUIT SG SGAV00

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 02,05,06 report with the FDA on 2011-03-10 for AORTIC VALVE & CONDUIT SG SGAV00 manufactured by Cryolife, Inc..

Event Text Entries

[1924032] As part of the cryovalve sg aortic human heart valve retrospective/prospective, multi-center cohort study, an explant form indicating the following event was received. According to the report, 4. 6 years after implant of the synergraft aortic valve and conduit allograft the allograft was explanted due to structural deterioration, calcification, and insufficiency, stenosis or obstruction of the allograft conduit, and stenosis or obstruction of the valve. The operative notes indicate there was moderately severe aortic allograft insufficiency with moderate aortic stenosis.
Patient Sequence No: 1, Text Type: D, B5


[9100484] This investigation is currently ongoing. Any additional information will be provided in the follow-up report.
Patient Sequence No: 1, Text Type: N, H10


[9403289] According to the report, 4. 6 years after implant of synergraft aortic valve & conduit allograft the allograft was explanted due to structural deterioration, calcification, insufficiency, stenosis/obstruction of allograft conduit, and stenosis/obstruction of the valve. The operative notes indicate there was moderately severe aortic allograft insufficiency with moderate aortic stenosis. The hospital indicated that the event was due to a failure of the allograft. The allograft was not returned so no direct observations can be made. A review of the processing records indicates that allograft met all processing specifications prior to release. A review of relevant literature indicates that although explantation of the valve approximately 4. 5 years after implant due to unacceptable hemodynamics could be considered early. However, it has been reported in the literature and is a known complication after cardiac valve implantation. It should also be noted that this patient received three previous aortic valve replacements prior to this procedure. The precise cause of the event cannot be determined from the available information; however, the report is consistent with features of structural valve deterioration. Structural valve deterioration is a known potential complication and is known to occur at an accelerated rate in the pediatric population. No further action is required at this time.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1063481-2011-00010
MDR Report Key2013240
Report Source02,05,06
Date Received2011-03-10
Date of Report2011-03-09
Date of Event2009-08-10
Date Mfgr Received2011-02-23
Device Manufacturer Date2002-04-12
Date Added to Maude2011-03-11
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactMR. BRYAN BROSSEAU
Manufacturer Street1655 ROBERTS BLVD., NW
Manufacturer CityKENNESAW GA 30144
Manufacturer CountryUS
Manufacturer Postal30144
Manufacturer Phone7704193355
Manufacturer G1CRYOLIFE, INC.
Manufacturer Street1655 ROBERTS BLVD., NW
Manufacturer CityKENNESAW GA 30144
Manufacturer CountryUS
Manufacturer Postal Code30144
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameAORTIC VALVE & CONDUIT SG
Generic NameCARDIAC ALLOGRAFT
Product CodeOHA
Date Received2011-03-10
Model NumberSGAV00
ID Number63137 (DONOR NUMBER)
Device Expiration Date2012-04-01
OperatorPHYSICIAN
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerCRYOLIFE, INC.
Manufacturer Address1655 ROBERTS BLVD., NW KENNESAW GA 30144 US 30144


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2011-03-10

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.